Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib


NCT01694277

Interventional

Phase 3

Active, not recruiting
The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.
Apr 30,2012
All
18 Years
N/A
258

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.